查看购物车
  • Traditional Chinese
  • English
  • Japanese
眼科治疗市场：全球按分子、治疗方式、适应症、给药途径、最终用户和地区划分 - 预测至 2030 年
市场调查报告书
商品编码
1759936

眼科治疗市场：全球按分子、治疗方式、适应症、给药途径、最终用户和地区划分 - 预测至 2030 年

Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 329 Pages | 订单完成后即时交付

价格

眼科治疗市场规模预计将从 2025 年的 195.2 亿美元成长到 2030 年的 262.8 亿美元，预测期内复合年增长率为 6.1%。

眼科治疗市场的成长主要源自于与老龄化相关的眼科疾病盛行率的上升，以及多种关键治疗药物的上市。此外，涵盖各种治疗模式的强大新药研发管线也促进了这一成长。亚太、拉丁美洲、中东和非洲等新兴经济体的地理扩张机会也为市场发展提供了支持。

研究范围
调查年份 2024-2030
基准年 2024
预测期 2024-2030
对价单位 金额（十亿美元）
部分 按分子、治疗方式、适应症、给药途径、最终用户和地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

由于视网膜疾病治疗领域尚未满足的需求、药物传输技术的进步以及近期产品核可，单株抗体 (mAb) 和融合蛋白预计将实现最高成长率。生物相似药和 KSI-301 等新产品的推出预计将加剧竞争并降低成本。再生元 (Regeneron) 和罗氏 (Roche) 等该市场的主要参与企业将对成长至关重要，而支付方的接受度和技术创新等因素也将显着影响市场动态。

此外，新兴市场对这些治疗方法的采用也日益增多，这得益于更便捷的取得途径和更实惠的价格，尤其是生物相似药。较短的给药週期使这些治疗方法更具成本效益。缓释性植入和基因疗法等技术创新也促进了该领域的成长。整体而言，生物相似药正在扩大供应，并提升治疗量。

预计美国将在2025年至2035年期间成为全球眼科药物市场中复合年增长率最高的国家。其快速成长的主要驱动力在于人口老化以及老龄化黄斑部病变(AMD) 和糖尿病黄斑部水肿(DME) 的高发生率。此外，美国还存在大量未满足的医疗需求、近期核准的Syfovre和Izervay等药物，以及前景看好的基因和细胞疗法研发管线。此外，美国也受惠于强大的研发生态系统、高效率的FDA核准流程和强劲的投资。此外，良好的报销环境、医疗保险覆盖范围以及民众接受昂贵治疗方法的意愿也对这一增长做出了重大贡献。

本报告研究了全球眼科治疗市场，并按分子、方式、适应症、给药途径、最终用户、区域趋势和公司概况进行细分。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章重要考察

第五章市场概述

  • 介绍
  • 市场动态
  • 技术分析
  • 影响客户业务的趋势/中断
  • 定价分析
  • 价值链分析
  • 生态系分析
  • 专利分析
  • 监管分析
  • 波特五力分析
  • 2025-2026 年重要会议与活动
  • 赎回方案
  • 主要相关人员和采购标准
  • 投资金筹措场景
  • 管道分析
  • 人工智慧对眼科药品市场的影响
  • 2025年美国关税对眼科药品市场的影响

第六章 眼科药物市场（依分子）

  • 介绍
  • 阿柏西普
  • 法利西单抗
  • 雷珠单抗
  • 其他的

7. 眼科药物市场（按方式）

  • 介绍
  • 单株抗体和融合蛋白
  • 低分子
  • 其他的

第八章眼科用药市场（依适应症）

  • 介绍
  • 老龄化黄斑部病变
  • 糖尿病视网膜病变（DR）
  • 糖尿病黄斑部水肿（DME）
  • 其他的

第九章 眼科用药市场（依管理途径）

  • 介绍
  • 玻璃体内
  • 局部的
  • 其他的

第 10 章眼科药物市场（依最终使用者）

  • 介绍
  • 医院
  • 长期照护机构
  • 专业中心

第十一章眼科用药市场（按地区）

  • 介绍
  • 北美洲
    • 北美宏观经济展望
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东
    • 中东宏观经济展望
    • 海湾合作委员会国家
    • 其他的
  • 非洲
    • 对医疗保健的更多关注将推动市场成长
    • 非洲宏观经济展望

第十二章竞争格局

  • 介绍
  • 主要参与企业的策略/优势
  • 2022-2024年收益分析
  • 2024年市场占有率分析
  • 公司估值象限：2024 年领先参与企业
  • 公司估值矩阵：Start-Ups/中小企业，2024 年
  • 估值和财务指标
  • 品牌/产品比较
  • 竞争场景

第十三章 公司简介

  • 主要参与企业
    • REGENERON PHARMACEUTICALS INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • BAYER AG
    • NOVARTIS AG
    • ABBVIE
    • APELLIS PHARMACEUTICALS
    • BIOGEN
    • BAUSCH+LOMB
    • ASTELLAS PHARMA INC.
    • FORMYCON AG
    • BIOCON
    • SANDOZ GROUP AG
    • SANTEN PHARMACEUTICAL CO., LTD.
    • INNOVENT
    • OUTLOOK THERAPEUTICS, INC.
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 其他公司（管道公司）
    • OCULAR THERAPEUTIX, INC.
    • OPTHEA LIMITED
    • KODIAK SCIENCES INC.
    • EYEPOINT PHARMACEUTICALS, INC.
    • ALVOTECH
    • CLEARSIDE BIOMEDICAL
    • SHANGHAI HENLIUS BIOTECH, INC.
    • ADVERUM BIOTECHNOLOGIES, INC.
    • REMEGEN
    • SPARINGVISION

第十四章 附录

Product Code: PH 9404

The ophthalmology drugs market is expected to grow from USD 19.52 billion in 2025 to USD 26.28 billion by 2030, registering a CAGR of 6.1% during the forecast period. The growth of the ophthalmology drugs market has primarily been driven by the increasing prevalence of age-related eye diseases and the availability of several key therapies that address these conditions. Additionally, a robust pipeline of new drugs across various treatment modalities contributes to this growth. Opportunities for geographic expansion in emerging economies, such as Asia Pacific, Latin America, the Middle East, and Africa, also support the market's development.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsMolecule, Modality, Indication, Route of Administration, End user
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

The monoclonal antibodies & fusion proteins segment is expected to grow at the highest CAGR during the study period.

Monoclonal antibodies (mAbs) & fusion proteins are anticipated to experience the highest growth rate due to unmet needs in treating retinal diseases, advancements in drug delivery, and recent product approvals. The introduction of biosimilars and upcoming products, such as KSI-301, is expected to enhance competition and reduce costs. Key players in this market, including Regeneron and Roche, are vital for growth, while factors like payor acceptance and technological innovations significantly influence market dynamics.

In addition, emerging markets are increasingly adopting these treatments, benefiting from better access and more affordable pricing, particularly with biosimilars. Less frequent dosing further enhances the cost-effectiveness of these therapies. Innovations such as sustained-release implants and gene therapies are also contributing to growth in this sector. Overall, biosimilars are expanding supply and increasing treatment volume.

The US is expected to grow at the highest CAGR in the global ophthalmology drugs market from 2025 to 2030.

The US is expected to experience the highest CAGR in the global ophthalmology drugs market between 2025 and 2035. This rapid growth is primarily driven by an aging population and the high prevalence of age-related macular degeneration (AMD) and diabetic macular edema (DME). Additionally, there are significant unmet medical needs, recent drug approvals like Syfovre and Izervay, and a promising pipeline for gene and cell therapies. The US also benefits from a strong research and development ecosystem, efficient FDA approval processes, and robust investment. Furthermore, a favorable reimbursement environment, Medicare coverage, and a willingness to adopt expensive therapies contribute significantly to this growth.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side (70%) and Demand Side (30%)
  • By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
  • By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

List of Key Companies Profiled in the Report:

F. Hoffmann-La Roche Ltd. (Switzerland), Regeneron, Pharmaceuticals Inc. (US), Bayer AG (Germany), AbbVie (US), Novartis AG (Switzerland), Bausch + Lomb (US), Apellis Pharmaceuticals (US), Biogen (US), Astellas Pharma Inc. (US), and Formycon AG (Germany), among others.

Research Coverage:

This research report categorizes the ophthalmology drugs market by molecule (aflibercept, faricimab, ranibizumab, and other molecules), modality (monoclonal antibodies & fusion proteins, small molecules, and other modalities), indication (age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and other indications), route of administration (intravitreal, topical, and other routes of administration), end user (hospitals, long-term care facilities, and specialty centers) and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the ophthalmology drugs market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the ophthalmology drugs market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the ophthalmology drugs market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (aging population and growing prevalence of vision disorders, strong drug pipeline and growing innovation efforts, increasing investments and strategic collaborations, and improved reimbursement policies), restraints (off-label drug use for various indications), opportunities (shifting focus on new drug modalities, expansion into emerging markets, and high unmet needs), and challenges (frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment).
  • Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the ophthalmology drugs market.
  • Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ophthalmology drugs market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the ophthalmology drugs market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Objectives of secondary research
      • 2.1.1.2 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
      • 2.1.2.2 Key objectives of primary research
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 GLOBAL MARKET ESTIMATION
      • 2.2.1.1 Product revenue analysis (bottom-up approach)
      • 2.2.1.2 Revenue share analysis of Regeneron Pharmaceuticals, Inc.
      • 2.2.1.3 MnM repository analysis
      • 2.2.1.4 Primary interviews
    • 2.2.2 INSIGHTS OF PRIMARY EXPERTS
    • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH)
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 OPHTHALMOLOGY DRUGS MARKET OVERVIEW
  • 4.2 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE
  • 4.3 OPHTHALMOLOGY DRUGS MARKET SHARE, BY END USER, 2024
  • 4.4 OPHTHALMOLOGY DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Aging population and growing prevalence of vision disorders
      • 5.2.1.2 Strong drug pipeline and growing innovation efforts
      • 5.2.1.3 Increasing investments and strategic collaborations
      • 5.2.1.4 Improved reimbursement policies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Off-label drug use for various indications
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Shifting focus on new drug modalities
      • 5.2.3.2 Expansion into emerging markets
      • 5.2.3.3 High unmet needs
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment
  • 5.3 TECHNOLOGY ANALYSIS
    • 5.3.1 KEY TECHNOLOGIES
      • 5.3.1.1 Hybridoma technology
      • 5.3.1.2 Recombinant DNA technology
      • 5.3.1.3 Antibody engineering
      • 5.3.1.4 Gene therapy
      • 5.3.1.5 Nanoformulations
    • 5.3.2 ADJACENT TECHNOLOGIES
      • 5.3.2.1 Optogenetic technology
      • 5.3.2.2 Drug-release technologies
      • 5.3.2.3 Ocular implant technologies
    • 5.3.3 COMPLEMENTARY TECHNOLOGIES
      • 5.3.3.1 3D printing and bioprinting
      • 5.3.3.2 Ocular imaging technologies
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.5 PRICING ANALYSIS
    • 5.5.1 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024
    • 5.5.2 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
    • 5.5.3 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • 5.7.1 OPHTHALMOLOGY DRUGS MARKET: ROLE OF RAW MATERIAL SUPPLIERS
    • 5.7.2 OPHTHALMOLOGY DRUGS MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES
    • 5.7.3 OPHTHALMOLOGY DRUGS MARKET: ROLE OF END USERS
    • 5.7.4 OPHTHALMOLOGY DRUGS MARKET: ROLE OF REGULATORY AUTHORITIES
  • 5.8 PATENT ANALYSIS
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 REGULATORY LANDSCAPE
      • 5.9.1.1 US
      • 5.9.1.2 Europe
      • 5.9.1.3 Emerging markets
    • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 PORTER'S FIVE FORCES ANALYSIS
    • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.10.2 BARGAINING POWER OF SUPPLIERS
    • 5.10.3 BARGAINING POWER OF BUYERS
    • 5.10.4 THREAT OF SUBSTITUTES
    • 5.10.5 THREAT OF NEW ENTRANTS
  • 5.11 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.12 REIMBURSEMENT SCENARIO
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.13.1 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS
  • 5.14 INVESTMENT & FUNDING SCENARIO
  • 5.15 PIPELINE ANALYSIS
  • 5.16 IMPACT OF ARTIFICIAL INTELLIGENCE ON OPHTHALMOLOGY DRUGS MARKET
    • 5.16.1 CHALLENGES IN DRUG DISCOVERY
    • 5.16.2 IMPACT OF AI ON DISCOVERY OF OPHTHALMOLOGY DRUGS
  • 5.17 IMPACT OF 2025 US TARIFFS ON OPHTHALMOLOGY DRUGS MARKET
    • 5.17.1 KEY TARIFF RATES
    • 5.17.2 PRICE IMPACT ANALYSIS
    • 5.17.3 KEY IMPACT ON VARIOUS REGIONS
      • 5.17.3.1 US
      • 5.17.3.2 Europe
      • 5.17.3.3 APAC
    • 5.17.4 MANUFACTURING INDUSTRY IMPACT
      • 5.17.4.1 Ophthalmology drug manufacturers

6 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE

  • 6.1 INTRODUCTION
  • 6.2 AFLIBERCEPT
    • 6.2.1 HIGH EFFICIENCY OF AFLIBERCEPT IN TREATING RETINAL DISEASES TO DRIVE MARKET GROWTH
  • 6.3 FARICIMAB
    • 6.3.1 GROWING ADOPTION AND POSITIVE OUTCOMES OF STUDIES TO SUPPORT MARKET GROWTH
  • 6.4 RANIBIZUMAB
    • 6.4.1 CLINICAL EFFICACY OF RANIBIZUMAB TO DRIVE ADOPTION
  • 6.5 OTHER MOLECULES

7 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY

  • 7.1 INTRODUCTION
  • 7.2 MONOCLONAL ANTIBODIES & FUSION PROTEINS
    • 7.2.1 GROWING FOCUS ON DEVELOPING NEW MABS TO DRIVE MARKET
  • 7.3 SMALL MOLECULES
    • 7.3.1 INCREASING INVESTMENTS AND RESEARCH TO DRIVE MARKET
  • 7.4 OTHER MODALITIES

8 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION

  • 8.1 INTRODUCTION
  • 8.2 AGE-RELATED MACULAR DEGENERATION
    • 8.2.1 WET AGE-RELATED MACULAR DEGENERATION
      • 8.2.1.1 Increasing demand for effective therapies to drive market
    • 8.2.2 DRY AGE-RELATED MACULAR DEGENERATION
      • 8.2.2.1 Large market opportunity for innovation to drive growth
  • 8.3 DIABETIC RETINOPATHY (DR)
    • 8.3.1 FEWER APPROVED DRUGS TO PRESENT MARKET OPPORTUNITIES
  • 8.4 DIABETIC MACULAR EDEMA (DME)
    • 8.4.1 GROWING ADOPTION OF APPROVED ANTI-VEGF DRUGS FOR DME TO DRIVE MARKET
  • 8.5 OTHER INDICATIONS

9 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 9.1 INTRODUCTION
  • 9.2 INTRAVITREAL
    • 9.2.1 HIGH EFFICACY OF INTRAVITREAL INJECTIONS IN TREATMENT OF MAJOR RETINAL DISEASES TO DRIVE MARKET
  • 9.3 TOPICAL
    • 9.3.1 EASE OF USE TO DRIVE DEMAND FOR TOPICAL DRUGS
  • 9.4 OTHER ROUTES OF ADMINISTRATION

10 OPHTHALMOLOGY DRUGS MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS
    • 10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO ENCOURAGE GROWTH
  • 10.3 LONG-TERM CARE FACILITIES
    • 10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
  • 10.4 SPECIALTY CENTERS
    • 10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH

11 OPHTHALMOLOGY DRUGS MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.2.2 US
      • 11.2.2.1 Rising investments in healthcare research and development to support growth
    • 11.2.3 CANADA
      • 11.2.3.1 Rising government initiatives to support ophthalmology drugs research and increasing drug approvals to support growth
  • 11.3 EUROPE
    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.3.2 GERMANY
      • 11.3.2.1 Rising focus on clinical research to drive market
    • 11.3.3 UK
      • 11.3.3.1 Ongoing advancements in technology to drive market growth
    • 11.3.4 FRANCE
      • 11.3.4.1 Growing investments and government support to drive market growth
    • 11.3.5 ITALY
      • 11.3.5.1 Growing investments and research to support market
    • 11.3.6 SPAIN
      • 11.3.6.1 Growing geriatric population to drive market growth
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.4.2 CHINA
      • 11.4.2.1 Large diabetic population to boost market
    • 11.4.3 JAPAN
      • 11.4.3.1 Growing aging population to intensify demand for effective treatments
    • 11.4.4 INDIA
      • 11.4.4.1 Increasing diabetic cases, government support, and growing availability of biosimilars to support market
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Strong biopharmaceutical sector to drive market growth
    • 11.4.6 SOUTH KOREA
      • 11.4.6.1 Strong R&D pipeline and increasing focus on research to support growth
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Significant rates of visual impairment in region to drive demand for advanced treatments
    • 11.5.3 MEXICO
      • 11.5.3.1 Growing research initiatives and innovations to support market growth
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Growing research initiatives and improving healthcare infrastructure to support growth
    • 11.6.3 REST OF MIDDLE EAST
  • 11.7 AFRICA
    • 11.7.1 GROWING FOCUS ON HEALTHCARE TO DRIVE MARKET GROWTH
    • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET
  • 12.3 REVENUE ANALYSIS, 2022-2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2024
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Molecule footprint
      • 12.5.5.4 Modality footprint
      • 12.5.5.5 Indication footprint
  • 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 12.6.5.1 Detailed list of key startups/SMEs
      • 12.6.5.2 Competitive benchmarking of startups/SMEs
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    • 12.7.1 VALUATION OF KEY PLAYERS
    • 12.7.2 FINANCIAL METRICS OF KEY PLAYERS
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES & APPROVALS
    • 12.9.2 DEALS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 REGENERON PHARMACEUTICALS INC.
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product approvals
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Right to win
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product launches & approvals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 BAYER AG
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product approvals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 NOVARTIS AG
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Product approvals
        • 13.1.4.3.2 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Right to win
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses & competitive threats
    • 13.1.5 ABBVIE
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
    • 13.1.6 APELLIS PHARMACEUTICALS
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product approvals
        • 13.1.6.3.2 Deals
    • 13.1.7 BIOGEN
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Product launches & approvals
    • 13.1.8 BAUSCH + LOMB
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Product launches & approvals
    • 13.1.9 ASTELLAS PHARMA INC.
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product approvals
        • 13.1.9.3.2 Deals
    • 13.1.10 FORMYCON AG
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 Product launches & approvals
        • 13.1.10.3.2 Deals
    • 13.1.11 BIOCON
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Product approvals
        • 13.1.11.3.2 Deals
    • 13.1.12 SANDOZ GROUP AG
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Product approvals
        • 13.1.12.3.2 Deals
    • 13.1.13 SANTEN PHARMACEUTICAL CO., LTD.
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Product launches
    • 13.1.14 INNOVENT
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
      • 13.1.14.3 Recent developments
        • 13.1.14.3.1 Product approvals
    • 13.1.15 OUTLOOK THERAPEUTICS, INC.
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Product approvals
        • 13.1.15.3.2 Deals
    • 13.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 13.1.16.1 Business overview
      • 13.1.16.2 Products offered
      • 13.1.16.3 Recent developments
        • 13.1.16.3.1 Product approvals
        • 13.1.16.3.2 Deals
  • 13.2 OTHER PLAYERS (PIPELINE COMPANIES)
    • 13.2.1 OCULAR THERAPEUTIX, INC.
    • 13.2.2 OPTHEA LIMITED
    • 13.2.3 KODIAK SCIENCES INC.
    • 13.2.4 EYEPOINT PHARMACEUTICALS, INC.
    • 13.2.5 ALVOTECH
    • 13.2.6 CLEARSIDE BIOMEDICAL
    • 13.2.7 SHANGHAI HENLIUS BIOTECH, INC.
    • 13.2.8 ADVERUM BIOTECHNOLOGIES, INC.
    • 13.2.9 REMEGEN
    • 13.2.10 SPARINGVISION

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 2 OPHTHALMOLOGY DRUGS MARKET: RISK ANALYSIS
  • TABLE 3 OPHTHALMOLOGY DRUGS MARKET: IMPACT ANALYSIS
  • TABLE 4 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024
  • TABLE 5 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024
  • TABLE 6 OPHTHALMOLOGY DRUGS MARKET: LIST OF RAW MATERIAL SUPPLIERS
  • TABLE 7 OPHTHALMOLOGY DRUGS MARKET: LIST OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES
  • TABLE 8 OPHTHALMOLOGY DRUGS MARKET: LIST OF END USERS
  • TABLE 9 OPHTHALMOLOGY DRUGS MARKET: LIST OF REGULATORY AUTHORITIES
  • TABLE 10 OPHTHALMOLOGY DRUGS MARKET: INDICATIVE LIST OF PATENTS, 2024
  • TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 OPHTHALMOLOGY DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 17 OPHTHALMOLOGY DRUGS MARKET: LIST OF CONFERENCES & EVENTS
  • TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 19 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS, BY END USER
  • TABLE 20 OPHTHALMOLOGY DRUGS IN CLINICAL PIPELINE, PHASE III (AS OF APRIL 2025)
  • TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 22 EXPORTS AND IMPORTS, BY REGION
  • TABLE 23 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 24 OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 25 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 26 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 27 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 28 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 29 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 30 OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 33 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 34 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 36 OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 37 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 38 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 42 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 43 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 44 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 47 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 48 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 49 OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 50 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 51 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 55 OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 56 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 57 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 58 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 61 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 62 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 63 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 65 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 67 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 68 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 69 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 71 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 75 OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 76 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 77 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 78 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 81 OPHTHALMOLOGY DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 82 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 83 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 84 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 89 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 90 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 91 OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 92 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 93 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 95 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 96 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 97 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 98 OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 99 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 100 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 102 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 104 OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 105 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 106 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 108 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 109 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 110 OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 111 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 114 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 115 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 116 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 117 OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 118 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 121 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 122 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 123 OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 124 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 125 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 127 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 128 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 129 OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 130 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 131 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 133 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 134 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 135 OPHTHALMOLOGY DRUGS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 136 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 137 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 139 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 140 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 141 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 142 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 143 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 144 US: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 145 US: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 146 US: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 147 US: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 148 US: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 149 US: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 150 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 151 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 152 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 153 CANADA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 154 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 155 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 156 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 157 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 158 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 159 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 160 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 161 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 162 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 163 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 164 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 165 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 166 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 167 GERMANY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 168 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 169 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 170 UK: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 171 UK: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 172 UK: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 173 UK: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 174 UK: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 175 UK: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 176 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 177 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 178 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 179 FRANCE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 180 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 181 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 182 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 183 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 184 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 185 ITALY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 186 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 187 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 188 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 189 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 190 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 191 SPAIN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 192 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 193 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 194 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 195 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 196 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 197 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 198 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 199 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 200 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 201 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 208 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 209 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 210 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 211 CHINA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 212 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 213 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 214 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 215 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 216 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 217 JAPAN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 218 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 219 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 220 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 221 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 222 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 223 INDIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 224 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 225 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 226 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 227 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 228 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 229 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 230 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 231 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 232 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 233 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 234 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 235 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 236 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 237 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 238 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 239 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 240 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 241 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 242 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 243 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 244 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 245 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 246 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 247 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 248 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 249 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 250 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 251 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 252 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 253 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 254 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 255 BRAZIL: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 256 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 257 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 258 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 259 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 260 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 261 MEXICO: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 262 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 263 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 264 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 265 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 266 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 267 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 268 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 269 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 270 MIDDLE EAST: MACROECONOMIC INDICATORS
  • TABLE 271 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 272 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 273 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 274 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 275 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 276 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 277 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 278 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 279 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 280 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 281 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 282 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 283 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 284 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 285 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 286 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 287 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 288 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 289 AFRICA: MACROECONOMIC INDICATORS
  • TABLE 290 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
  • TABLE 291 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
  • TABLE 292 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
  • TABLE 293 AFRICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 294 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
  • TABLE 295 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 296 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET
  • TABLE 297 OPHTHALMOLOGY DRUGS MARKET: DEGREE OF COMPETITION
  • TABLE 298 OPHTHALMOLOGY DRUGS MARKET: REGION FOOTPRINT
  • TABLE 299 OPHTHALMOLOGY DRUGS MARKET: MOLECULE FOOTPRINT
  • TABLE 300 OPHTHALMOLOGY DRUGS MARKET: MODALITY FOOTPRINT
  • TABLE 301 OPHTHALMOLOGY DRUGS MARKET: INDICATION FOOTPRINT
  • TABLE 302 OPHTHALMOLOGY DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 303 OPHTHALMOLOGY DRUGS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
  • TABLE 304 OPHTHALMOLOGY DRUGS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-MAY 2025
  • TABLE 305 OPHTHALMOLOGY DRUGS MARKET: DEALS, JANUARY 2022-MAY 2025
  • TABLE 306 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
  • TABLE 307 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED
  • TABLE 308 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 309 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 310 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 311 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 312 BAYER AG: COMPANY OVERVIEW
  • TABLE 313 BAYER AG: PRODUCTS OFFERED
  • TABLE 314 BAYER AG: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 315 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 316 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 317 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 318 NOVARTIS AG: DEALS, JANUARY 2021-MAY 2025
  • TABLE 319 ABBVIE: COMPANY OVERVIEW
  • TABLE 320 ABBVIE: PRODUCTS OFFERED
  • TABLE 321 APELLIS PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 322 APELLIS PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 323 APELLIS PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 324 APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021-MAY 2025
  • TABLE 325 BIOGEN: COMPANY OVERVIEW
  • TABLE 326 BIOGEN: PRODUCTS OFFERED
  • TABLE 327 BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 328 BAUSCH + LOMB: COMPANY OVERVIEW
  • TABLE 329 BAUSCH + LOMB: PRODUCTS OFFERED
  • TABLE 330 BAUSCH + LOMB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 331 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
  • TABLE 332 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
  • TABLE 333 ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 334 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021-JULY 2024
  • TABLE 335 FORMYCON AG: COMPANY OVERVIEW
  • TABLE 336 FORMYCON AG: PRODUCTS OFFERED
  • TABLE 337 FORMYCON AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 338 FORMYCON AG: DEALS, JANUARY 2021-MAY 2025
  • TABLE 339 BIOCON: COMPANY OVERVIEW
  • TABLE 340 BIOCON: PRODUCTS OFFERED
  • TABLE 341 BIOCON: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 342 BIOCON: DEALS, JANUARY 2021-MAY 2025
  • TABLE 343 SANDOZ GROUP AG: COMPANY OVERVIEW
  • TABLE 344 SANDOZ GROUP AG: PRODUCTS OFFERED
  • TABLE 345 SANDOZ GROUP AG: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 346 SANDOZ GROUP AG: DEALS, JANUARY 2021-JULY 2024
  • TABLE 347 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 348 SANTEN PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED
  • TABLE 349 SANTEN PHARMACEUTICAL CO., LTD: PRODUCT LAUNCHES, JANUARY 2021-MAY 2025
  • TABLE 350 INNOVENT: COMPANY OVERVIEW
  • TABLE 351 INNOVENT: PRODUCTS OFFERED
  • TABLE 352 INNOVENT: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
  • TABLE 353 OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 354 OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED
  • TABLE 355 OUTLOOK THERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2022-MAY 2025
  • TABLE 356 OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2022-MAY 2025
  • TABLE 357 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 358 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 359 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS, JANUARY 2022-MAY 2025
  • TABLE 360 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022-MAY 2025
  • TABLE 361 OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW
  • TABLE 362 OPTHEA LIMITED: COMPANY OVERVIEW
  • TABLE 363 KODIAK SCIENCES INC.: COMPANY OVERVIEW
  • TABLE 364 EYEPOINT PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 365 ALVOTECH: COMPANY OVERVIEW
  • TABLE 366 CLEARSIDE BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 367 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW
  • TABLE 368 ADVERUM BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 369 REMEGEN: COMPANY OVERVIEW
  • TABLE 370 SPARINGVISION: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 OPHTHALMOLOGY DRUGS MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 OPHTHALMOLOGY DRUGS MARKET: RESEARCH DESIGN
  • FIGURE 3 OPHTHALMOLOGY DRUGS MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 4 OPHTHALMOLOGY DRUGS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 5 OPHTHALMOLOGY DRUGS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 6 PRODUCT REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)
  • FIGURE 7 REVENUE SHARE ANALYSIS OF REGENERON PHARMACEUTICALS, INC. (2024)
  • FIGURE 8 OPHTHALMOLOGY DRUGS MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 9 OPHTHALMOLOGY DRUGS MARKET: BOTTOM-UP APPROACH
  • FIGURE 10 OPHTHALMOLOGY DRUGS MARKET: CAGR PROJECTIONS
  • FIGURE 11 OPHTHALMOLOGY DRUGS MARKET: DATA TRIANGULATION
  • FIGURE 12 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 GEOGRAPHIC ANALYSIS: OPHTHALMOLOGY DRUGS MARKET
  • FIGURE 18 GROWING PREVALENCE OF RETINAL DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH
  • FIGURE 19 AFLIBERCEPT ACCOUNTED FOR LARGEST SHARE OF OPHTHALMOLOGY DRUGS MARKET IN NORTH AMERICA IN 2024
  • FIGURE 20 HOSPITALS TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 21 NORTH AMERICA LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL OPHTHALMOLOGY DRUGS MARKET DURING FORECAST PERIOD
  • FIGURE 22 OPHTHALMOLOGY DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 24 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
  • FIGURE 25 OPHTHALMOLOGY DRUGS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 26 OPHTHALMOLOGY DRUGS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 27 OPHTHALMOLOGY DRUGS MARKET: PATENT PUBLICATION TRENDS, JURISDICTION, AND TOP APPLICANT ANALYSIS (JANUARY 2014-DECEMBER 2024)
  • FIGURE 28 OPHTHALMOLOGY DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 29 KEY STAKEHOLDERS IN BUYING PROCESS OF OPHTHALMOLOGY DRUGS, BY MODALITY
  • FIGURE 30 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT
  • FIGURE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT
  • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2022-2024 (USD MILLION)
  • FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
  • FIGURE 35 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 36 OPHTHALMOLOGY DRUGS MARKET: COMPANY FOOTPRINT
  • FIGURE 37 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 38 EV/EBITDA OF KEY PLAYERS
  • FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
  • FIGURE 40 OPHTHALMOLOGY DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 41 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 43 BAYER AG: COMPANY SNAPSHOT (2024)
  • FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 45 ABBVIE: COMPANY SNAPSHOT (2024)
  • FIGURE 46 APELLIS PHARMACEUTICALS: COMPANY SNAPSHOT (2024)
  • FIGURE 47 BIOGEN: COMPANY SNAPSHOT (2024)
  • FIGURE 48 BAUSCH + LOMB: COMPANY SNAPSHOT (2024)
  • FIGURE 49 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 50 FORMYCON AG: COMPANY SNAPSHOT (2024)
  • FIGURE 51 BIOCON: COMPANY SNAPSHOT (2024)
  • FIGURE 52 SANDOZ GROUP AG: COMPANY SNAPSHOT (2024)
  • FIGURE 53 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 54 INNOVENT: COMPANY SNAPSHOT (2024)
  • FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)